Rein Therapeutics Inc.
RNTXHealthcareNASDAQBiotechnology
Scan Results
Daily timeframeRein Therapeutics Inc., a biopharmaceutical company, focuses on developing medicines to address unmet medical needs in orphan pulmonary and fibrosis indications in the United States. With a market capitalization of $51.3M, it sits in micro-cap territory. The company's lead product candidate is LTI-03, a peptide, which is in Phase 2 clinical trial for the treatment of idiopathic pulmonary fibrosis (IPF).
Market Cap
$51.3M
Beta
1.35
P/E (TTM)
—
P/E (Fwd)
—
EPS (TTM)
$-1.81
EPS (Fwd)
—
ROE
-96.4%
ROA
-21.0%
Cash
$40.6M
Total Debt
$0
Free CF
-$7.8M
52W Change
-51.2%
Annual Financials
Cash vs Debt
Where RNTX stands vs its 150-day and 200-day moving averages
As of the October 20, 2026 close, RNTX finished 45.54% below its 150-day moving average ($1.01) and 48.11% below its 200-day moving average ($1.06). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is RNTX overbought or oversold?
At the October 20, 2026 close, RNTX's RSI(14) was 28.1, in oversold territory (below 30). The MACD histogram was negative, so short-term momentum leaned bearish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
Rein Therapeutics Inc. reports $40.6M in cash and $0 in total debt. Free cash flow is running at -$7.8M, which bears watching. Negative free cash flow can be acceptable during heavy investment periods but needs to improve over time. ROE of -96.4% points to negative capital efficiency, indicating how much profit the company produces per dollar of shareholder equity.
The company is burning cash at the operating level, which is not unusual for growth-phase companies but adds risk if it persists. Understanding these risk dimensions helps frame what to watch going forward as conditions evolve for Rein Therapeutics Inc. and its sector.